Logo image of NVNO

ENVVENO MEDICAL CORP (NVNO) Stock Fundamental Analysis

USA - NASDAQ:NVNO - US29415J1060 - Common Stock

0.968 USD
+0.02 (+1.73%)
Last: 10/3/2025, 8:00:02 PM
0.97 USD
+0 (+0.21%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

2

NVNO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NVNO as it has an excellent financial health rating, but there are worries on the profitability. NVNO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NVNO had negative earnings in the past year.
In the past year NVNO has reported a negative cash flow from operations.
NVNO had negative earnings in each of the past 5 years.
In the past 5 years NVNO always reported negative operating cash flow.
NVNO Yearly Net Income VS EBIT VS OCF VS FCFNVNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -63.07%, NVNO is not doing good in the industry: 69.63% of the companies in the same industry are doing better.
The Return On Equity of NVNO (-69.78%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.07%
ROE -69.78%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
NVNO Yearly ROA, ROE, ROICNVNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

NVNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVNO Yearly Profit, Operating, Gross MarginsNVNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NVNO has more shares outstanding
NVNO has more shares outstanding than it did 5 years ago.
NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVNO Yearly Shares OutstandingNVNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
NVNO Yearly Total Debt VS Total AssetsNVNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

NVNO has an Altman-Z score of -4.29. This is a bad value and indicates that NVNO is not financially healthy and even has some risk of bankruptcy.
NVNO has a Altman-Z score of -4.29. This is in the lower half of the industry: NVNO underperforms 67.54% of its industry peers.
There is no outstanding debt for NVNO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.29
ROIC/WACCN/A
WACCN/A
NVNO Yearly LT Debt VS Equity VS FCFNVNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

NVNO has a Current Ratio of 11.81. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
NVNO's Current ratio of 11.81 is amongst the best of the industry. NVNO outperforms 95.29% of its industry peers.
NVNO has a Quick Ratio of 11.81. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
NVNO's Quick ratio of 11.81 is amongst the best of the industry. NVNO outperforms 96.34% of its industry peers.
Industry RankSector Rank
Current Ratio 11.81
Quick Ratio 11.81
NVNO Yearly Current Assets VS Current LiabilitesNVNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

NVNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.08%, which is quite good.
EPS 1Y (TTM)16.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NVNO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.86% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVNO Yearly Revenue VS EstimatesNVNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2018 2019 2026 2027 2028 5M 10M 15M 20M 25M
NVNO Yearly EPS VS EstimatesNVNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVNO Price Earnings VS Forward Price EarningsNVNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVNO Per share dataNVNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as NVNO's earnings are expected to grow with 12.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.4%
EPS Next 3Y12.02%

More info and screens

0

5. Dividend

5.1 Amount

NVNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVVENO MEDICAL CORP

NASDAQ:NVNO (10/3/2025, 8:00:02 PM)

After market: 0.97 +0 (+0.21%)

0.968

+0.02 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners23.33%
Inst Owner Change42.55%
Ins Owners0.81%
Ins Owner Change0%
Market Cap18.63M
Analysts43.33
Price Target12.75 (1217.15%)
Short Float %14.18%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.51%
Min EPS beat(2)-15.55%
Max EPS beat(2)36.56%
EPS beat(4)2
Avg EPS beat(4)8.25%
Min EPS beat(4)-15.55%
Max EPS beat(4)36.56%
EPS beat(8)6
Avg EPS beat(8)13%
EPS beat(12)7
Avg EPS beat(12)6.26%
EPS beat(16)8
Avg EPS beat(16)-14.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.07%
ROE -69.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.81
Quick Ratio 11.81
Altman-Z -4.29
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)23.4%
Cap/Depr(5y)99.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.45%
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.99%
OCF growth 3YN/A
OCF growth 5YN/A